AbbVie UK Golden Ticket
AbbVie is excited to launch the 2022 AbbVie UK Golden Ticket in collaboration with We Are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community.
For AbbVie, this demonstrates our commitment to investing in the UK’s world class life sciences sector and accelerating the delivery of life-changing innovations to patients
The Golden Ticket programme awards one year of free-lab space, funded by AbbVie, and access to core facilities and services at selected WAPG locations*, membership to the WAPG community of scientists, technologists and entrepreneurs, and support from AbbVie’s world leading global scientists, business leaders and mentors.
AbbVie will grant one Golden Ticket to an early-stage UK life science biotech company in 2022.
AbbVie is looking for early-stage biotech companies that fit the following criteria:
Focused on science / technology with potential to generate transformational therapies in areas that align strategically with AbbVie’s therapeutic areas of interest (listed below)
- Developing therapeutic platform technologies, including gene therapy, novel cell therapy, gene editing, or novel drug-discovery or platform technologies
- Exclusions: Diagnostics, Devices, Research Tools, and Healthcare Services/IT
* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park